Annicka Reuss

Annicka Reuss

Auto-generated profile, based on publicly available information

Annicka Reuss

Unit for Healthcare-Associated Infections, Surveillance of Antibiotic Resistance and Consumption, Department of Infectious Disease Epidemiology, Robert Koch Institute, 10113 Berlin, Germany

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2019 in Antimicrobial Resistance & Infection Control
Verified
Journal Article
Open access
PDF file
RMRobby Markwart
Robby Markwart
NWNiklas Willrich
Niklas Willrich
SHSebastain Haller
Sebastain Haller
INInes Noll
Ines Noll
UKUwe Koppe
Uwe Koppe
ARAnnicka Reuss
Annicka Reuss
Due to limited therapeutic options, vancomycin-resistant Enterococcus faecium (VREF) is of great clinical significance. Recently, rising proportions of vancomycin resistance in enterococcal infections have been reported worldwide. This study aims to describe current epidemiological trends of VREF in German hospitals and to identify factors that are associated with an increased likelihood of vancomycin resistance in clinical E. faecium isolates. 2012 to 2017 data from routine vancomycin susceptibility testing of 35,906 clinical E. faecium isolates from 148 hospitals were analysed using data from the German Antimicrobial Resistance Surveillance System. Descriptive statistical analyses and uni- and multivariable regression analyses were performed to investigate the impact of variables, such as year of sampling, age and region, on vancomycin resistance in clinical E. faecium isolates. From 2014 onwards the proportions of clinical E. faecium isolates exhibiting resistance to vancomycin increased from 11.2% (95% confidence interval [CI] 9.4–13.3%) to 26.1% (95% CI 23.1–29.4%) in 2017. The rise of VREF proportions is primarily observed in the southern regions of Germany, whereas northern regions do not show a major increase. In the Southwest and Southeast, VREF proportions increased from 10.8% (95% CI 6.9–16.5%) and 3.8% (95% CI 3.0–11.5%) in 2014 to 36.7% (95% CI 32.9–40.8%) and 36.8% (95% CI 29.2–44.7%) in 2017, respectively. VREF proportions were considerably higher in isolates from patients aged 40–59 years compared to younger patients. Further regression analyses show that in relation to secondary care hospitals, E. faecium samples collected in specialist care hospitals and prevention and rehabilitation care centres are more likely to be vancomycin-resistant (odds ratios: 2.4 [95% CI 1.2–4.6] and 2.4 [95% CI 1.9–3.0], respectively). No differences in VREF proportions were found between female and male patients as well as between different clinical specimens. The proportion of VREF is increasing in German hospitals, particularly in southern regions in Germany. Increased efforts in infection control and antibiotic stewardship activities accounting for local resistance patterns are necessary to combat the spread of VREF in Germany.

22 April 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
MBMichael Brandl
Michael Brandl
AHAlexandra Hoffmann
Alexandra Hoffmann
NWNiklas Willrich
Niklas Willrich
ARAnnicka Reuss
Annicka Reuss
FRFelix Reichert
Felix Reichert
SHSebastain Haller
Sebastain Haller
Data from surveillance networks show that men have a higher incidence rate of infections with anti-microbial-resistant (AMR) pathogens than women. We systematically analysed data of infections and colonisations with AMR pathogens under mandatory surveillance in Germany to quantify gender-specific differences. We calculated incidence-rates (IR) per 100,000 person–years for invasive infections with Methicillin-resistant Staphylococcus aureus (MRSA), and for infections or colonisations with carbapenem-non-susceptible Acinetobacter spp. (CRA), and Enterobacterales (CRE), using the entire German population as a denominator. We limited the study periods to years with complete notification data (MRSA: 2010–2019, CRA/CRE: 2017–2019). We used Poisson regression to adjust for gender, age group, federal state, and year of notification. In the study periods, IR for all notifications were 4.2 for MRSA, 0.90 for CRA, and 4.8 for CRE per 100,000 person-–years. The adjusted IR ratio for infections of men compared to women was 2.3 (95% confidence interval [CI]: 2.2–2.3) for MRSA, 2.2 (95%CI: 1.9–2.7) for CRA, and 1.7 (95%CI: 1.6–1.8) for CRE. Men in Germany show about double the risk for infection with AMR pathogens than women. This was also true for colonisations, where data were available. Screening procedures and associated hygiene measures may profit from a gender-stratified approach.

1 April 2014 in Emerging Infectious Diseases
Verified
Journal Article
Open access
ARAnnicka Reuss
Annicka Reuss
ALAnnette Litterst
Annette Litterst
CDChristian Drosten
Christian Drosten
MSMichael Seilmaier
Michael Seilmaier
MBMerle Böhmer
Merle Böhmer
UBUdo Buchholz
Udo Buchholz
On March 19, 2013, a patient from United Arab Emirates who had severe respiratory infection was transferred to a hospital in Germany, 11 days after symptom onset. Infection with Middle East respiratory syndrome coronavirus (MERS-CoV) was suspected on March 21 and confirmed on March 23; the patient, who had contact with an ill camel shortly before symptom onset, died on March 26. A contact investigation was initiated to identify possible person-to-person transmission and assess infection control measures. Of 83 identified contacts, 81 were available for follow-up. Ten contacts experienced mild symptoms, but test results for respiratory and serum samples were negative for MERS-CoV. Serologic testing was done for 53 (75%) of 71 nonsymptomatic contacts; all results were negative. Among contacts, the use of FFP2/FFP3 face masks during aerosol exposure was more frequent after MERS-CoV infection was suspected than before. Infection control measures may have prevented nosocomial transmission of the virus.

19 August 2010 in BMC Public Health
Verified
Journal Article
Open access
PDF file
ARAnnicka M Reuss
Annicka M Reuss
MFMarcel Feig
Marcel Feig
LKLutz Kappelmayer
Lutz Kappelmayer
ASAnette Siedler
Anette Siedler
TETim Eckmanns
Tim Eckmanns
GPGabriele Poggensee
Gabriele Poggensee
Since July 2004, routine varicella vaccination is recommended by the German Standing Vaccination Committee in Germany. Health Insurance Funds started to cover vaccination costs at different time points between 2004 and 2006 in the Federal States. Nationwide representative data on vaccination coverage against varicella of children under two years of age are not available. We aimed to determine varicella vaccination coverage in statutory health insured children under two years of age in twelve German Federal States using data from associations of statutory health insurance physicians (ASHIPs), in order to investigate the acceptance of the recommended routine varicella vaccination programme.

3 December 2010 in Deutsches Ärzteblatt international
Verified
Journal Article
Closed access
ARAnnicka M. Reuss
Annicka M. Reuss
DWDietmar Walter
Dietmar Walter
MFMarcel Feig
Marcel Feig
LKLutz Kappelmayer
Lutz Kappelmayer
UBUdo Buchholz
Udo Buchholz
GPGabriele Poggensee
Gabriele Poggensee
Influenza is a viral disease that is transmitted mainly via large-droplets. The pandemic potential of influenza viruses was illustrated by the subtype influenza A (H1N1), which occurred de novo in 2009. The seasonal influenza wave usually starts in...

4 May 2010 in Das Gesundheitswesen
Verified
Journal Article
Closed access
PDF file
ARA. Reuss
A. Reuss
MFM. Feig
M. Feig
LKL. Kappelmayer
L. Kappelmayer
TET. Eckmanns
T. Eckmanns
GPG. Poggensee
G. Poggensee
Hintergrund: Im Rahmen des KV-Sentinels, einem gemeinsamen Projekt des Robert Koch-Instituts und der 17 Kassenärztlichen Vereinigungen, werden seit 2004 pseudonymisierte Abrechnungsdaten von den Kassenärztlichen Vereinigungen an das Robert Koch-Institut übermittelt. Ziel des Beitrages ist es zu beschreiben, mit welchen methodischen Verfahren die Daten aufbereitet werden, um Impfquoten und Inzidenzen von impfpräventablen Erkrankungen zu bestimmen. Weiterhin wird diskutiert, welche Limitationen bei der Interpretation der Daten zu beachten sind. Methoden: Daten zu allen Impfleistungen und zu den Erkrankungen Keuchhusten, Masern, Mumps, Windpocken und Gürtelrose werden über die Abrechnungsziffern der Impfleistungen und die ICD-10 Kodes aus dem Datenbestand der Kassenärztlichen Vereinigungen abgefragt und pseudonymisiert an das Robert Koch-Institut übermittelt, wo sie einer Qualitätsprüfung unterzogen werden. Studienpopulation ist die gesetzlich krankenversicherte Bevölkerung in Deutschland (85,5% der deutschen Bevölkerung). Die Impfquoten errechnen sich durch die Anzahl der geimpften Personen bezogen auf die Anzahl der gesetzlich krankenversicherten Personen. Die Inzidenzen werden durch die Anzahl der erkrankten Personen bezogen auf 100 000 gesetzlich krankenversicherte Personen berechnet. Ergebnisse: Alle 17 Kassenärztlichen Vereinigungen nehmen am Projekt teil. Insgesamt wurden für die Jahre 2004–2007 95 905 605 Datensätze zu Impfleistungen und 4 570 919 Datensätze zu Diagnosen übermittelt. Über 99% der Datensätze sind strukturell und inhaltlich fehlerfrei und können ausgewertet werden. Im Jahr 2007 lagen die monovalenten Impfungen gegen Influenza (39%) und Frühsommer-Meningoenzephalitis (17%) anteilig an allen Impfungen am höchsten. Von 1 893 790 Diagnosen, die in 2006 und 2007 bei der Abrechnung angegeben wurden, sind 1 415 660 (75%) aktuelle Diagnosen. Von diesen sind 70% mit der Diagnosesicherheit „gesicherte Diagnose” versehen. Am häufigsten wurden ICD-10 Kodes für Gürtelrose (57%) und Windpocken (33%) angegeben. Schlussfolgerung: Die Abrechnungsdaten zu Impfungen ermöglichen erstmals die Bestimmung von bundesweiten Impfquoten für alle Altersgruppen der gesetzlich krankenversicherten Bevölkerung. Die Validierung der Daten zu Impfungen ist anhand vorliegender Daten aus Sentinel-Systemen bzw. aus anderen Forschungsprojekten möglich. Die vorliegenden Diagnosedaten der akuten, impfpräventablen Infektionskrankheiten müssen mit Vorsicht interpretiert werden, da es ohne externe Validierung schwierig ist abzuschätzen, ob eine Unter- oder eine Übererfassung vorliegt. Hier besteht weiterer Forschungsbedarf. Background: The KV-Sentinel, established in 2004, is a joint project of the Robert Koch Institute and the 17 associations of statutory health insurance physicians (ASHIPs) in Germany. The ASHIPs provide anonymous physicians billing data to the Robert Koch Institute. The aim of this article is to describe methodological approaches for processing these routine data to determine vaccination coverage and incidence of vaccine preventable diseases. Furthermore, we discuss limitations in interpreting these data. Methods: The ASHIPs perform a data query of all vaccinations and of ICD-10 codes for pertussis, measles, mumps, varicella and herpes zoster and send anonymous data to the Robert Koch Institute. We perform routine tests to ensure data quality. Study population is the statutory health insured population (85.5% of the German population). Vaccination coverage is determined by the number of vaccinated persons and the number of statutory health insured persons. Incidence is calculated by the number of diseased persons per 100 000 statutory health insured persons. Results: All 17 ASHIPs participate in the project. In total, 95 905 605 data records for vaccinations and 4 570 919 data records for pertussis, measles, mumps, varicella and herpes zoster were provided from 2004 to 2007. After performing routine tests with regard to structure and content of data, more than 99% of the data records can be analysed. In 2007, the majority of given vaccinations were monovalent vaccinations against influenza (39%) and tick-borne encephalitis (17%). In 2006 and 2007, 1 893 790 data records for diagnoses were provided. Of these, 75% were acute diagnoses and of these 70% were confirmed diagnoses. Most often, ICD-10 codes for herpes zoster (57%) and varicella (35%) were reported. Conclusion: Nationwide vaccination coverage of statutory health insured persons by age group can be determined by using billing data. It is possible to validate billing data of vaccinations with available data from other studies. Interpretation of billing data of acute vaccine preventable diseases remains challenging because it is difficult to assess potential under- or overestimation without the possibility of external validation. Therefore, further research is needed.